DENVER, Dec. 11, 2012 /PRNewswire/ -- Accelr8 Technology Corporation (NYSE MKT: AXK) will hold its 2012 Annual Meeting of Shareholders (the "Annual Meeting") at 2:30 p.m., local time, on Wednesday, December 12, 2012, at the Warwick Hotel Denver, 1776 Grant Street, Denver, Colorado 80203.
Progress towards the company's IVD product launch continues, with management expecting to be in development through 2014, launching in 2015, with additional clinical trials continuing through 2016.
Accelr8 Technology Corporation (www.accelr8.com) is focused on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The Company's BACcel platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that decrease time to result while maintaining high sensitivity and specificity.
Disclaimer Regarding Forward-Looking Statements
Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the Company's filings with the SEC. The Company does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.
SOURCE Accelr8 Technology Corporation